SCHEMBL17456009

SCHEMBL17456009

c1cnc(-c2ccncc2)c(OC2CCN(Cc3cnccn3)CC2)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SCN9A Q15858 4/20 0.47
▸ CYP11B1 P15538 1/20 0.39
▸ CYP11B2 P19099 1/20 0.39
▸ ALDH1A1 P00352 4/20 0.38
▸ DRD4 P21917 1/20 0.37
▸ SIGMAR1 Q99720 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SCN5A Q14524 1/20 0.37
▸ LTA4H P09960 1/20 0.36
▸ CHRM4 P08173 1/20 0.36
▸ UTS2R Q9UKP6 1/20 0.36
▸ SCN8A Q9UQD0 1/20 0.36
▸ EGFR P00533 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ SLC5A7 Q9GZV3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17455954 0.89 ALDH1A1 (0.48) SCN9ACYP11B1CYP11B2ALDH1A1DRD4
SCHEMBL17455949 0.86 SCN9A (0.52) SCN9AALDH1A1SCN5A
SCHEMBL17456050 0.86 SCN9A (0.49) SCN9ACYP11B1CYP11B2DRD4SIGMAR1
SCHEMBL17455921 0.85 CYP11B1 (0.42) SCN9ACYP11B1CYP11B2ALDH1A1LTA4H
SCHEMBL17455973 0.84 SCN9A (0.46) SCN9ASCN5A
SCHEMBL17456021 0.83 SCN9A (0.43) SCN9ACYP11B1CYP11B2DRD4SCN5A
SCHEMBL17455968 0.83 SMN1; SMN2 (0.53) SCN9ACYP11B1CYP11B2ALDH1A1DRD4
SCHEMBL17456018 0.83 CYP11B1 (0.42) CYP11B1CYP11B2CHRM4LMNA
SCHEMBL17455988 0.81 KDM4E (0.46) SCN9ACYP11B1CYP11B2SCN8ASMN1; SMN2
SCHEMBL17455993 0.81 IKBKE (0.37) CYP11B1CYP11B2SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 SCN9A 565/4885CYP11B1 88/4885CYP11B2 82/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback